JPMorgan Starts EyePoint Pharmaceuticals, Inc. (EYPT) at Overweight, 'An Eyeful of Opportunities in EYP-1901'
Tweet Send to a Friend
(Updated - January 22, 2024 4:29 AM EST)
JPMorgan analyst Tessa Romero initiates coverage on EyePoint Pharmaceuticals, Inc. (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Tessa Romero initiates coverage on EyePoint Pharmaceuticals, Inc. (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
